Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global label-free detection market was valued at US$ 6.0 billion in 2021 and is expected to register a revenue CAGR of 15% to reach US$ 24.27 billion by 2030.

Label-free Detection Market Fundamentals

The term label-free detection systems refer to integrated systems used to study biomolecular interactions without reducing the labels or causing autofluorescence. These technologies enable the rapid and real-time discovery of novel medications. Label-free detection methods are used to detect biochemical and cell-based assays. These techniques are used to detect biomolecules and their interactions. They have proved to be an excellent R&D tool for the biotech and pharmaceutical industries.

The global label-free detection market is expected to show revenue growth at a significant pace during the forecast period as a result of collaborations between pharmaceutical companies and academic institutions, as well as an increase in drug discovery programs across developed and developing countries. Label-free technology enables researchers to conduct studies using novel methodologies that solely provide end-point results. Labels have the potential to introduce items by inactivating or reducing the ability of the biomolecule of interest to interact.

[36236734]

Label-free Detection Market Dynamics 

The rise in R&D activities in the pharmaceutical and biotechnology fields is propelling the global label-free detection market revenue growth. Label-free detection techniques are in great demand due to an increase in outsourcing various pharmaceutical activities and R&D activities by academic institutions. These approaches are in high demand as they effectively manage the complexity of various signaling pathways. Furthermore, label-free detection approaches avoid the usage of autofluorescence and spatial interference, increasing their acceptance. Furthermore, the market is predicted to rise as a result of joint efforts by governments and private groups to organize seminars and spread awareness among end-users about the benefits of employing label-free detection techniques. In addition, the continuous efforts of firms to develop cutting-edge label-free detecting techniques are expected to help the industry flourish in the upcoming years.

Label-free Detection Market Ecosystem 

The global label-free detection market has been analyzed from four perspectives: technology, products, application, and region. 

Label-free Detection Market by Technology

[5234155]

Based on the technology, the global label-free detection market is segmented into cellular dielectric spectroscopy, bio-layer interferometry, surface plasmon resonance, and optical waveguide grating technology.

The surface plasma resonance segment dominates the global market. Furthermore, the same segment is predicted to have the greatest revenue CAGR during the forecast period. This can be ascribed to the technology's high sensitivity and widespread application in adjusting specificity, affinity, and kinetic parameters during macromolecule binding.

Label-free Detection Market by Products

Based on the products, the global label-free detection market has been segmented into instruments, consumables, biosensor chips, and microplates.

The consumables segment dominates the market owing to the factors such as continuing breakthroughs in label-free detection technologies and high consumption volumes in the biopharmaceutical and biotechnology sectors.

Label-free Detection Market by Application 

Based on the application, the global label-free detection systems have been segmented into binding thermodynamics, binding kinetics, hit confirmation, and lead generation.

The binding kinetics segment dominates the market due to the rising demand for medications with a broad therapeutic index, advances in structural biology, and increased R&D activities to detect coronavirus using a label-free detection approach.

Label-free Detection Market by Region

Based on the region, the global label-free detection market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.

North America dominated the global label-free detection market in 2021. Favorable regulatory and political conditions, an ever-increasing number of local biotech enterprises, and expanding demand for innovative biopharmaceuticals have contributed to the rise in demand for label-free detection devices. The trend is projected to continue due to the market’s significant quantity of catch-up potential and the increased availability of biotech drugs. Increased funding for academic and public-sector research institutes is also driving demand for label-free products in North America.

Asia Pacific is the fastest-growing region in the global label-free detection market. Several Asian countries, such as China and India, are expected to expand at the fastest revenue CAGR during the forecast period. Strict regulatory requirements in various industries from these countries are driving demand for sample analysis and quality control tools. Furthermore, investments in laboratory infrastructure are becoming increasingly appealing, particularly in China. Furthermore, the regional market revenue growth is projected to be driven by government-supported efforts to stimulate innovation in the healthcare industry. China invested more in R&D than the United States for the first time in 2021, increasing its proportion of R&D spending.

Label-free Detection Market Competitive Landscape 

The prominent market players in the global label-free detection market include:

• Danaher Corporation
• GE Healthcare
• F. Hoffmann-La Roche Ltd.
• PerkinElmer Inc.
• Horiba Ltd.
• Agilent Technologies, Inc.
• Mettler Toledo
• Corning Inc.
• Bioptix Inc.
• BioNavis Limited 
• Attana AB

Manufacturers continue pushing the bounds of sensitivity and throughput as knowledge of the benefits of label-free detection grows. Key market players are accelerating their R&D initiatives to produce unique products to achieve considerable growth in existing and new business categories. They are also focusing on improving their overall positions in key markets by launching products.

Label-free Detection Market Strategic Developments 

• In March 2021, Sartorius’ Life Science Group unveiled the revolutionary high-performance Octet® R range of systems, the company’s most recent update to its line of label-free analytical tools. Users will be able to find the right balance between throughput requirements and their financial goals with three distinct models.
• In October 2020, HORIBA announced the ADS EVO automatic driving system, a driving robot for automobile testing. The ADS EVO improves vehicle testing effectiveness by lowering the number of repeat tests, laboratory running expenses, total test time, and the number of human errors.
• In July 2020, Hitachi Ltd. partnered with ThinkCyte Inc. to create an artificial intelligence (AI)-powered cell analysis and sorting system. With this agreement, the companies intended to combine ThinkCyte Inc’s high-throughput technology with Hitachi Ltd’s label-free single-cell sorting expertise to create large-scale devices.
• In March 2020, Danaher Corporation acquired General Electric Company's life sciences division's Biopharma unit. The purchased company, Cytiva, was expected to be operated as a separate entity under Danaher Corporation’s biosciences division.

Frequently Asked Questions About This Report